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Summary
 
The 
 
b
 
-chemokine RANTES (regulated on activation, normal T cell expressed and secreted)
suppresses the infection of susceptible host cells by macrophage tropic strains of HIV-1. This
effect is attributed to interactions of this chemokine with a 7-transmembrane domain receptor,
CCR5, that is required for virus–cell fusion and entry. Here we identify domains of RANTES
that contribute to its biological activities through structure–function studies using a new mono-
clonal antibody, mAb 4A12, isolated from mice immunized with recombinant human RANTES.
This monoclonal antibody (mAb) blocked the antiviral activity of RANTES in infectivity as-
says with HIV-1
 
Bal
 
, and inhibited the mobilization of intracellular Ca
 
2
 
1
 
 elicited by RANTES,
yet recognized this chemokine bound to cell surfaces. Epitope mapping using limited proteoly-
sis, reversed phase high-performance liquid chromatography, and mass spectrometry suggest
that residues 55–66 of RANTES, which include the COOH-terminal 
 
a
 
-helical region impli-
cated as the glycosaminoglycan (GAG) binding domain, overlap the determinant recognized by
mAb 4A12. This is supported by affinity chromatography studies, which showed that
RANTES could be eluted specifically by heparin from a mAb 4A12 immunoaffinity matrix.
Removal of cell surface GAGs by enzymatic digestion greatly reduced the ability of mAb 4A12
to detect RANTES passively bound on cell surfaces and abrogated the ability of RANTES to
elicit an intracellular Ca
 
2
 
1
 
 signal. Taken together, these studies demonstrate that the COOH-
terminal 
 
a
 
-helical region of RANTES plays a key role in GAG-binding, antiviral activity, and
intracellular Ca
 
2
 
1
 
 signaling and support a model in which GAGs play a key role in the biologi-
cal activities of this chemokine.
Key words:
 
b
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T
 
he discovery of the antiviral effect of 
 
b
 
-chemokines
on M-tropic isolates of HIV-1 (1) and the identifica-
tion of 7-transmembrane domain, G protein–coupled
chemokine receptors as entry cofactors for HIV-1 (2–7) set
the stage for the development of novel approaches to con-
trol HIV-1 infections. Studies using in vitro
 
 
 
mutagenesis
have identified domains important for coreceptor function
(8–25), and revealed that coreceptor activity can be dissoci-
ated from receptor activation (8, 22–26), indicating that it
might be possible to block virus entry using chemokine an-
alogues without aberrant stimulation of cellular responses.
In addition to the interactions between 
 
b
 
-chemokines
and the canonical 7-transmembrane domain receptors, two
new reports suggest a role for cell surface glycosaminogly-
cans (GAGs)
 
1
 
 in the ability of RANTES (regulated on acti-
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Abbreviations used in this paper:
 
 FBS, fetal bovine serum; GAG, glycosami-
noglycan; MIP, macrophage inflammatory protein; RANTES, regulated
on activation, normal T cell expressed and secreted; TCID
 
50
 
, tissue cul-
ture dose that infects 50% of cultures.
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vation, normal T cell expressed and secreted) to block in-
fection by HIV-1. In the first of these studies (27),
enzymatic removal of cell surface GAGs increased the con-
centrations of RANTES required to block infection with
HIV-1. In the second study (28), 
 
b
 
-chemokines com-
plexed with GAGs were found to be secreted by CTL
clones and similar complexes formed in vitro with heparan
sulfate were more effective than free 
 
b
 
-chemokines at
blocking the infection of macrophages with M-tropic
HIV-1. Our studies, described below, identify a domain of
RANTES that contributes to the binding of GAGs, lending
further support for a role of GAGs in the biological activities
of 
 
b
 
-chemokines. We show that a new monoclonal anti-
body, mAb 4A12, which blocks both the antiviral effect and
the mobilization of intracellular Ca
 
2
 
1
 
 elicited by RANTES,
recognizes an epitope that overlaps the GAG-binding do-
main of this 
 
b
 
-chemokine. Taken together, our studies
strongly support the involvement of cell surface GAGs in
both the antiviral effect of RANTES and the ability of
RANTES to signal responsive cells.
 
Materials and Methods
 
Cell Culture.
 
PM1 and HUT-78 cells were maintained in cul-
ture in RPMI 1640 (GIBCO BRL, Gaithersburg, MD) supple-
mented with 10% fetal bovine serum (FBS; GIBCO BRL) and 50
 
m
 
g/ml gentamycin (Sigma Chemical Co., St. Louis, MO), de-
noted hereafter as complete medium. Human PBMCs were ob-
tained from healthy donors (American Red Cross, Baltimore,
MD) by centrifugation on Ficoll-Hypaque density gradients. PHA
5 
 
m
 
g/ml (Sigma Chemical Co.) and 20 U/ml recombinant human
IL-2 (Boehringer Mannheim, Indianapolis, IN) were used to acti-
vate PBMCs for 3 d in complete medium at 37
 
8
 
C in a humidified
 
incubator at a 7% CO
 
2
 
/air mixture. After activation, the cells were
washed and cultured in complete medium containing 20 U/ml
IL-2, which was replaced every third day until the cells were used.
 
Isolation of mAbs.
 
Murine hybridomas were isolated by fusing
the spleens of BALB/cJ mice hyperimmunized with recombinant
human RANTES (R&D Systems, Minneapolis, MN) with the
P3X63.AG8.653 fusion partner using the standard methods of
Lewis and colleagues (29–33). The methods for fusion, screening
by ELISA, hybridoma cloning, and hybridoma propagation were
as previously described (29–33).
 
Infectivity Assays.
 
PM1 cells were infected for 2 h at 37
 
8
 
C
with HIV-1
 
BaL
 
 at a ratio of 2 
 
3 
 
10
 
6
 
 cells to 500 TCID
 
50
 
 in 5 ml
culture medium. Cells were then washed to remove virus and
placed in tissue culture wells at a density of 2 
 
3 
 
10
 
5
 
 cells in 250
 
m
 
l complete medium. A stock solution of purified mAb 4A12
was diluted in culture medium containing an equal concentration
of normal mouse IgG and subsequent serial dilutions were made
in this medium to maintain a constant total immunoglobulin con-
centration of 66 nM. Serial dilutions of mAb 4A12 were preincu-
bated with 10 nM RANTES for 1 h at room temperature and
250 
 
m
 
l of the antibody/chemokine mix then added to the cells to
achieve a total culture volume of 500 
 
m
 
l and a final RANTES
concentration of 5 nM. The cells were fed 3 d after infection by
removing 250 
 
m
 
l of medium and replacing with an equal volume
of fresh medium containing the appropriate concentrations of
mAb 4A12, RANTES, or the mAb 4A12/RANTES mixture.
Levels of infection were determined 7–10 d after infection by
measuring HIV-1
 
 P 
 
24 levels using an antigen capture ELISA
(DuPont, Inc., Cambridge, MA). All assays were carried out in
triplicate.
 
Flow Cytometry.
 
PM1 cells were aliquoted at 10
 
6
 
 cells/tube
using 12 
 
3 
 
75-mm culture tubes. Cells were treated one of three
ways: (
 
a
 
) RANTES was added at a concentration of 128 nM; (
 
b
 
)
RANTES was preincubated with a fivefold molar excess of mAb
4A12; or (
 
c
 
) RANTES was not included in the cell incubation. In
conditions 
 
a
 
 and 
 
c
 
 mAb 4A12 was added to the cells. In condition
 
b
 
 the mAb 4A12/RANTES complex was added to the cells. Fi-
nally, in all three conditions PE-conjugated anti–mouse IgG
(anti-IgG-PE; Sigma Chemical Co.) was used to detect the mAb.
In all cases cells were incubated on ice for 1 h (45 min for anti-
IgG) and kept in PBS supplemented with 2% FBS and 0.1% so-
dium azide. Cells were washed twice between each incubation.
All samples were finally fixed in 1% paraformaldehyde and ana-
lyzed on a FACScalibur
 
Ò
 
 flow cytometer (Becton Dickinson, San
Jose, CA). To stain for the presence of CCR5, cells were ali-
quoted as described above. mAb 2D7 (PharMingen, San Diego,
CA) was incubated at the concentration suggested by the manu-
facturer with the cells and binding of this mAb to cells was de-
tected with anti-IgG-PE as above. Similarly, cells were washed
twice between incubations, incubated with both antibodies for 45
min each on ice, and kept in PBS supplemented with 2% FBS
and 0.1% sodium azide.
 
Glycanase Treatment of Cells.
 
PM1 cells or activated PBMCs
were incubated with 1 U/ml each of heparinase II, heparinase III,
and chondroitinase ABC (Sigma Chemical Co.) for 1 h at 37
 
8
 
C.
As a control, untreated PBMCs were simultaneously incubated in
culture medium only. After 1 h the cells were washed twice, once
in culture medium and once in PBS supplemented with 2% FBS
and 0.1% sodium azide. Cells were kept on ice until stained with
the indicated antibodies.
 
Measurement of Intracellular Ca
 
2
 
1
 
 Responses by Flow Cytometry.
 
PBMCs were isolated from healthy normal donors (described
above) and prepared for analysis of Ca
 
2
 
1
 
 signaling as we have de-
scribed previously (34). RANTES, mAb 4A12, or preincubated
mAb 4A12/RANTES (as described above) were used to induce
Ca
 
2
 
1
 
 mobilization and analyzed by FACScalibur
 
Ò
 
 (34, 35).
 
Staphylococcus aureus V8 Protease Digestion of RANTES and Sep-
aration of Fragments by Reversed Phase HPLC.
 
Recombinant hu-
man RANTES (carrier free) (R&D Systems) and 
 
S
 
.
 
 aureus
 
 V8
protease (Sigma Chemical Co.) were incubated at 37
 
8
 
C. After 1 h,
the digestion mixture was placed on ice and kept until analyzed
by HPLC. Undigested as well as digested RANTES were puri-
fied by reversed phase HPLC using a C
 
18
 
 column (Waters Instru-
ments, Milford, MA) equilibrated in H
 
2
 
O containing 0.1% TFA.
A linear 0–65% gradient of acetonitrile in TFA/H
 
2
 
O was used to
elute fragments over a 45 min time course.
 
Dot Blotting.
 
Dot blotting was carried out as previously de-
scribed (33) except that PVDF membranes were used instead of
nitrocellulose membranes.
 
Heparin Elution of RANTES Bound to a mAb 4A12 Immunoaffin-
ity Matrix.
 
An immunoaffinity matrix was prepared by co-
valently coupling 1 mg of purified mAb 4A12 IgG2a to activated
CH Sepharose 4B (Sigma Chemical Co.) using previously de-
scribed methods (36). Native RANTES, purified from serum-
free culture medium from F3b clone 19 cells (35) and then over a
HiTrap heparin affinity FPLC column (Amersham Pharmacia
Biotech, Piscataway, NJ) equilibrated in 10 mM Tris HCl, pH
7.6. The bound proteins, including RANTES, eluted with 2 M
NaCl in the same buffer. The heparin column eluate was diluted
twofold with 10 mM Tris HCl, pH 7.6, and applied over a 1 h 
1919
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period at room temperature to the mAb 4A12 immunoaffinity
column equilibrated in the same buffer. The unbound fraction
was collected, the matrix was washed with PBS, and heparin sul-
fate (1 mg/ml) in PBS was run into the column. The column was
clamped and allowed to incubate for 30 min at room tempera-
ture. The material eluted from the column by the heparin/PBS
solution was collected and the column washed again with PBS.
The column was subjected to a second round of elution with 0.2 M
glycine, pH 2.5, and the eluate fraction collected. The amounts
of RANTES in the affinity column load, unbound, and eluate
fractions were determined by ELISA (R&D Systems).
 
Results
 
mAb 4A12 Blocks the Antiviral Effect of RANTES.
 
Hybrido-
mas were isolated from BALB/cJ mice hyperimmunized
with RANTES as described in Materials and Methods, and
three stable clones reactive with RANTES were identified
by ELISA. Preliminary studies showed that these mAb are
specific for RANTES as judged by the lack of reactivity
with macrophage inflammatory protein (MIP)-1
 
a
 
 and
MIP-1
 
b
 
 in ELISA. In additional studies, purified IgG from
each of the hybridomas blocked the antiviral effect of
RANTES; however, mAb 4A12 was 
 
z
 
10–20-fold more
efficient in this assay than the other two and was thus cho-
sen for further study. A representative experiment showing
mAb 4A12 inhibition of antiviral effects is shown in Fig. 1.
In this experiment, incubation of a limiting concentra-
tion of RANTES with increasing concentrations of mAb
4A12 resulted in a dose-dependent reversal of the antiviral
effect (Fig. 1). No reversal was obtained with normal
mouse IgG alone (Fig. 1, 0 nM mAb 4A12). Note that the
total IgG concentration remained constant in this assay by
dilution of mAb 4A12 into medium containing normal
mouse IgG. Similar results were obtained by adding mAb
4A12 and RANTES to PM1 cells infected with HIV-1
 
BaL
 
without preincubation (data not shown).
 
mAb 4A12 Blocks Intracellular Ca
 
2
 
1
 
 Responses Elicited by
RANTES.
 
The ability of mAb 4A12 to block intracellu-
lar Ca
 
2
 
1
 
 responses elicited by RANTES was evaluated us-
ing flow cytometry. These studies used normal human
PBMCs activated with PHA plus IL-2 for 3 d followed by
expansion with IL-2 alone for 9 d. The activated PBMCs
were washed and loaded with the calcium-sensitive indica-
tor dye Fluo-3 and intracellular Ca
 
2
 
1
 
 responses were deter-
mined by flow cytometry in response to RANTES as de-
scribed previously (34, 35). In the experiment shown in
Fig. 2, 3 nM RANTES elicited a characteristic intracellular
Ca
 
2
 
1
 
 response in the activated PBMCs (
 
triangles
 
). Preincu-
bation of 15 nM mAb 4A12 with 3 nM RANTES abro-
gated this response (Fig. 2, 
 
thin line
 
). In our early experi-
ments, neither preincubation of RANTES with a variety of
control IgG2a mAb nor incubation of cells alone with mAb
4A12 yielded unexpected activities, and therefore these
controls were excluded from subsequent studies, including
the one shown in Fig. 2. Taken together these data show
that mAb 4A12 blocks the ability of RANTES to induce
intracellular Ca
 
2
 
1
 
 signaling in addition to the antiviral ef-
fect of this chemokine.
 
mAb 4A12 Recognizes an Epitope Overlapping the GAG
Binding Domain of RANTES.
 
Because mAb 4A12 blocks
both the antiviral effect and intracellular Ca
 
2
 
1
 
 signaling
elicited by RANTES, it is likely that the epitope recog-
nized by this mAb overlaps a structure that plays a key role
in these biological responses. Accordingly, epitope map-
ping was undertaken to identify this structure. Early map-
ping studies carried out using synthetic overlapping pep-
tides failed to identify a reactive peptide, suggesting the
epitope recognized by mAb 4A12 is discontinuous. There-
fore, a different strategy was taken in which RANTES was
digested with 
 
S
 
.
 
 aureus
 
 V8 protease that cleaves selectively
at glutamic and aspartic acid residues. After digestion, five
distinct polypeptide peaks were obtained by reversed phase
HPLC (Fig. 3 
 
A
 
). Dot blot analyses revealed that the peaks
1, 2, and 3 were not reactive with mAb 4A12, whereas
peaks 4 and 5 were (Fig. 3 
 
B
 
).
Figure 1. mAb 4A12 blocks the antiviral effect of RANTES. Purified
mAb 4A12 was diluted serially in complete culture medium supple-
mented with sufficient normal mouse IgG to maintain the total murine Ig
concentration at 66 nM. Aliquots of mAb 4A12 were incubated with
RANTES at a final concentration of 22 nM for 1 h at ambient tempera-
ture. These complexes were added to PM1 cells previously incubated for
2 h at 378C with 500 TCID50 of HIV-1Bal and were washed before addi-
tion of the complexes. The cultures were fed on day 3, and infection was
quantified on day 9 by p24 antigen capture ELISA.
Figure 2. mAb 4A12 blocks
intracellular Ca21 responses elic-
ited by RANTES. Normal hu-
man PBMCs were activated with
PHA plus IL-2 for 3 d followed
by expansion with IL-2 alone for
9 d at which time they were used
to measure intracellular Ca21 re-
sponses. The cells were washed
and loaded with the indicator dye Fluo-3 and responses to RANTES
measured as by flow cytometry described in Materials and Methods and
references 34 and 35. In this experiment, the cells were stimulated with
RANTES at 3 nM or with a mixture of 3 nM RANTES plus 15 nM
mAb 4A12. The mixture of RANTES and mAb 4A12 was prepared by
incubating these two reagents for 1 h at ambient temperature before use
in the assay. RANTES was prepared identically before use in this assay as
the positive control. Calcium mobilization is shown as a change in mean
fluorescence over time, where 1 time unit is equal to 0.2 s. 
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Sequence analyses by either mass spectrometry or NH
 
2
 
-
terminal Edman degradation were used to identify the pep-
tides in each peak as listed in Table 1. Peak 1 mapped to
residues 55–60 in the COOH terminus of RANTES. The
observed molecular mass was 846, which corresponds well
to the predicted mass of 845. Peak 2 also mapped to the
COOH terminus of RANTES, in this case to residues 61–
66. The observed mass of 738.8 was in agreement with the
predicted mass of 737.9 for this peptide. NH
 
2
 
-terminal se-
quencing of peak 3 revealed two peptides; one peptide se-
quence corresponded to the first nine residues in the NH
 
2
 
terminus of RANTES, whereas the second peptide se-
quence corresponded to residues 27–35. Assignment of the
penultimate residue in the latter peptide was ambiguous
and most likely corresponds to the cysteine at position 34
in RANTES. The observed mass for the NH
 
2
 
-terminal
peptide was 2,922, which is consistent with the predicted
mass of 2,924.8 for a fragment that includes residues 1–26
of RANTES. As expected, this fragment terminates with a
glutamic acid, which is the recognition site of V8 protease.
The observed mass for the second peptide was 6,101,
which is consistent with the predicted mass of 6,104.7 for a
fragment corresponding to residues 27–54 of RANTES.
The 1–26 and 27–54 peptides include cysteines at positions
10 and 34 that are disulfide bonded in native RANTES.
Thus, peak 3 contains a polypeptide that is comprised of
two disulfide-bonded peptides corresponding to residues
1–54 of RANTES with a single cleavage at the glutamic
acid located at position 26.
Peak 4, as determined by amino acid analysis, produced
results consistent with a fragment of RANTES correspond-
ing to residues 1–66. Such a product is predicted to occur
after V8 digestion of RANTES due to a single cleavage at
glutamic acid residue 66 that removes the last two residues
(methionine and serine) in the COOH terminus of the
molecule. Peak 5 contained undigested RANTES as shown
by NH
 
2
 
-terminal sequencing and mass spectrometry. The
NH
 
2
 
-terminal sequence was SPYSS, which corresponds to
the first five residues of RANTES, and the observed mass
was 7,846, which corresponds to the predicted mass of
7,851.9 for uncleaved RANTES.
Because mAb 4A12 reacted with the fragment corre-
sponding to residues 1–66 but not with that corresponding
to residues 1–54, it is probable that epitope recognized by
Figure 3. HPLC profile and
mAb 4A12 reactivity of V8 pro-
tease digests of RANTES. (A)
Reversed phase HPLC profile
of RANTES digest products.
RANTES was digested with 10 U
S. aureus V8 protease as de-
scribed in Materials and Meth-
ods. The digestion mixture was
purified by reversed phase HPLC
using a C18 column (Waters In-
struments) equilibrated in H2O
containing 0.1% TFA. A linear
gradient of TFA/H2O and ace-
tonitrile/H2O was used to elute fragments over 45 min. (B) Dot blot. Fractions from reversed-phase HPLC were pulled onto a PVDF membrane using a
vacuum manifold and washed three times with Tris-buffered saline. The blot was then blocked with BLOTTO (33) and incubated with 5 mg/ml mAb
4A12. Binding was detected using anti–mouse IgG alkaline phosphatase and visualized by chemiluminescence as described previously (33). R, RANTES
(positive control); C, irrelevant peptide (negative control).
Table 1. RANTES Cleavage Products after Digestion with S. aureus V8 Protease
Fraction
number
Corresponding
residues MS/MS NH2-terminal sequence
Molecular masses by mass
spectrometry
Theoretical Observed
dalton
1 55–60 KKWVRE NT 845 846
2 61–66 YINSLE NT 737.9 738.8
3 1–54 NT SPYSSDTTP/YFYTSGK*S 2924.8/6104.7 2922/6101
4§ 1–66 ND ND ND
5 1–68 NT SPYSS 7851.9 7846
NT, not tested; ND, not detected.
§Fraction 4 was identified by amino acid analysis.1921 Burns et al.
this antibody overlaps residues 55–66 of RANTES al-
though the epitope must involve additional residues as the
peptides corresponding to this region were not reactive
with mAb 4A12 (our unpublished data). Residues 55–66
include the a-helical region of RANTES (Fig. 4) and the
corresponding region has been implicated as the GAG-
binding domain for several (37–39) but not all (40)
chemokines. This raised the possibility that mAb 4A12
might recognize an epitope associated with the GAG-bind-
ing domain of RANTES.
This possibility was tested by affinity chromatography in
which heparin was used to elute RANTES from the mAb
4A12 immunoaffinity matrix. A preparation of native
RANTES (z100 mg), purified from the culture superna-
tant of a transformed human T cell (F3b clone 19; refer-
ence 35) was captured by the mAb 4A12 affinity column.
The unbound fraction was then collected, and the column
was washed (flow-through fraction; Fig. 5, black bar) and
then treated for 30 min at ambient temperature with 1 mg/
ml heparin in PBS (Fig. 5, hatched bar). To ensure that hep-
arin removed all of the bound RANTES, the column was
then washed and again treated with 0.2 M glycine, pH 2.5
(Fig. 5, stippled bar), which we routinely use to elute
RANTES from mAb 4A12 immunoaffinity columns. As
shown in Fig. 5, most of the RANTES captured by the
mAb 4A12 affinity column was eluted with heparin. In this
experiment, 17.5 mg RANTES was found in the flow-
through fraction and 71.2 mg RANTES was eluted with
heparin. By contrast, only 2.3 mg RANTES was eluted us-
ing the pH 2.5 buffer. These results demonstrate competi-
tive binding for RANTES between heparin and mAb
4A12, which is consistent with the epitope mapping data
suggesting that this mAb recognizes an epitope in the
GAG-binding domain of RANTES.
mAb 4A12 Displays Two Patterns of Reactivity with
RANTES and the Binding of this Chemokine to Cell Surface
GAGs. Because the above studies suggest that mAb 4A12
recognizes an epitope overlapping the GAG-binding do-
main of RANTES, we used flow cytometry to investigate
the ability of this mAb to detect RANTES bound to GAGs
on the cell surface. In one experimental condition, (Fig. 6,
Group 1) PM1 cells were incubated with RANTES (128
nM) followed by exposure to mAb 4A12. Finally, mAb
4A12 binding was detected by flow cytometry using anti-
IgG-PE. In a second experimental condition (Fig. 6, Group
2) PM1 cells were treated identically except that RANTES
and a fivefold molar excess of mAb 4A12 were mixed for 1 h
before incubation with the cells. Comparison of the flow
histograms for groups 1 and 2 in Fig. 6 shows that mAb
4A12 detects RANTES prebound to PM1 cells. No signal
was observed when mAb 4A12 was excluded from the as-
say (data not shown). Thus, once RANTES is bound to
the cell surface, it can be detected by mAb 4A12. How-
ever, if RANTES was admixed with mAb 4A12 before ex-
posure to PM1 cells, no signal was obtained (Fig. 6; com-
pare flow histograms for groups 2 and 3). Similar results
have been obtained using 125I-RANTES (our unpublished
results). Thus, preincubation with mAb 4A12 blocks the
binding of RANTES to cell surfaces. This paradoxical re-
sult is explained most readily by the recent observation that
binding to cell surface GAGs induces oligomerization of
RANTES (reference 41 and see Discussion). Therefore,
mAb 4A12 is recognizing the GAGs binding domain of a
molecule that is not directly binding to GAGs but instead to
other RANTES molecules. Two additional series of exper-
iments were carried out to examine this possibility further.
Figure 4. Stereo drawing of RANTES depicting a-helical region and
cationic sites. This structure was generated using the averaged nuclear
magnetic resonance coordinates for the file 1RTO.PDB obtained from the
Protein Data Bank at Brookhaven National Laboratories (Brookhaven,
NY). These coordinates were described originally in reference 48. The
drawing is rendered in “cross-eyed” stereo and uses the following color
scheme: yellow, b-sheets; pink, a-helix; blue, cationic site 1 (Arg 44, Lys 45,
Arg 47); green, cationic site 2 (Lys 55, Lys 56, Arg 59); cyan, NH2 terminus
of RANTES (Ser 1); white, all other residues of RANTES.
Figure 5. Elution of RANTES
by heparin from mAb 4A12 col-
umn. Native RANTES purified
from the supernatant of the
HTLV-1 transformed cell line,
F3b (35), was adsorbed onto an
affinity matrix of mAb 4A12.
The column was washed and se-
quentially eluted with heparin
(1 mg/ml in PBS) and 0.2 M
glycine, pH 2.5. RANTES was quantified by capture ELISA as described
in Materials and Methods. Black bar, flow through; hatched bar, heparin
eluate; stippled bar, pH 2.5 eluate.
Figure 6. Detection of RANTES
bound to cell surfaces by flow
cytometry. PM1 cells in Group 1
(green line) were treated with 128
nM RANTES followed by a
45-min incubation with a five-
fold molar excess of mAb 4A12
as described in Materials and
Methods. Cells in Group 3 (red
line) were not incubated with
RANTES, but treated with 4A12 alone. Cells in Group 2 (blue line) were
treated with RANTES and 4A12 that had been previously incubated to-
gether. In all conditions 4A12 binding was visualized with anti-IgG-PE
and the fluorescence intensity was determined by flow cytometry.1922 mAb against the Glycosaminoglycan Binding Domain of RANTES
First, cell surface GAGs were removed enzymatically
from cells to establish that the binding of RANTES de-
tected by mAb 4A12 is dependent on GAGs. In these stud-
ies, we used activated PBMCs that were treated either with
medium alone or with a mixture of glycanases including
heparinase II and III and chondroitinase ABC as described
in Materials and Methods. The treated cells were incubated
with RANTES and cell surface binding was detected with
mAb 4A12 followed by anti-IgG-PE. As shown in Fig. 7 a,
incubation of activated PBMCs with medium alone before
exposure to RANTES produced the expected signal with
mAb 4A12 (thick line), whereas no signal was observed in
the absence of RANTES (thin line). By contrast, the signal
was reduced markedly when activated PBMCs were incu-
bated with the glycanase mixture before exposure to
RANTES followed by detection with mAb 4A12 and anti-
IgG-PE (Fig. 7 c). Background signals were not changed by
removal of cell surface GAGs (compare thin lines in a and
c). Thus, the removal of cell surface GAGs from the acti-
vated PBMCs dramatically reduced the binding of RANTES
detected by mAb 4A12. The removal of GAGs had no ef-
fect on CCR5 expression (Fig. 7, b and d) as detected by
anti-CCR5 mAb 2D7. This result shows that the effect of
glycanase treatment is specific for RANTES and not due to
a nonspecific removal of other cell surface markers. Fur-
thermore, glycanase treatment had no effect on other cell
surface markers including CD3, CD8, CXCR4, and CD4
(data not shown). Thus, most of the RANTES binding de-
tected by mAb 4A12 and flow cytometry is dependent on
cell surface GAGs. We have obtained identical results for
biotinylated MIP-1a and MIP-1b when PM1 cells are gly-
canase treated and binding is detected by flow cytometry
using FITC-streptavidin as well as with the binding of 125I-
RANTES to glycanase-treated PBMCs (our unpublished
results).
Second, a titration curve was constructed to determine
whether the observed binding is saturable (Fig. 8). In these
experiments, both PM1 cells and their parental cell line,
HUT-78, were used. PM1 cells express the 7-transmem-
brane domain receptors that bind RANTES, whereas the
HUT-78 cells do not (42). The cells were incubated with
RANTES at concentrations ranging from 0.1–1,000 nM
and binding was detected as described in Fig. 5 using mAb
4A12. A plot of the mean fluorescence intensity deter-
mined for each histogram versus RANTES concentration
is shown in Fig. 8. Binding was detected only at RANTES
concentrations .30 nM and increased exponentially above
this concentration without an obvious plateau even at
1,000 nM, which was the highest concentration tested.
This pattern of binding is consistent with the selective de-
tection of “low affinity” interactions between RANTES
and GAGs the cell surface. This binding is at least 100-fold
higher than the 0.3 nM binding constant described for
binding of 125I-RANTES to activated lymphocytes (refer-
ence 43 and our manuscript in preparation). The exponen-
tial binding observed by flow cytometry at concentrations
of RANTES .30 nM and the lack of saturation is consis-
tent with the “recruitment” of RANTES monomers onto
GAG-bound RANTES to form oligomers as reported (41).
Intracellular Signaling Induced by RANTES Is Blocked by
Removal of Cell Surface GAGs. The studies described above
suggest that mAb 4A12 blocks the antiviral effect of RANTES
by inhibiting the interaction between this chemokine and cell
surface GAGs. Unfortunately, this hypothesis is difficult to
test directly, as removal of cell surface GAGs reduces infec-
tion by HIV-1 (27). Thus, we sought additional relation-
ships between cell surface GAGs and the biological activity
of RANTES. The ability of RANTES to elicit intracellular
Ca21 signals is well known (44) and we used this response
to determine whether the removal of cell surface GAGs af-
Figure 7. Glycanase treatment blocks RANTES binding. PBMCs were
treated a mixture of glycanases consisting of 1 U/ml each heparinase II,
heparinase III, and chondroitinase ABC or medium alone. Cells were
stained for RANTES binding as detected with 4A12 or CCR5 expression
as detected with 2D7. Fluorescence intensity was analyzed by flow cy-
tometry. A and C represent RANTES binding (thick line) as compared
with background (thin line) in untreated and glycanase treated cells, re-
spectively. B and D represent 2D7 anti-CCR5 (thick line) staining as com-
pared with isotype control (thin line) in untreated and glycanase-treated
cells, respectively.
Figure 8. Titration curve of RANTES on PM1 and HUT-78 cells.
Hut-78 cells (u) and their derivative cell line PM1 (s) were incubated
with serial dilutions of RANTES ranging from 0.3 nM to 1 mM. After
incubation, mAb 4A12 (33 mM) was added to all conditions and binding
was detected with anti-IgG-PE. Fluorescence intensity was determined
by flow cytometry as described in Materials and Methods.1923 Burns et al.
fects the biological activity of RANTES. We were not able
to elicit Ca21 signals in PM1 cells using any of a variety of
agonists (including RANTES and anti-CD3), and there-
fore the experiment was carried out using primary PHA-
activated lymphocytes grown for 9 d on IL-2 and treated
with the glycanase mixture as described for Fig. 7. Con-
trol populations of the same cells were sham-treated with
medium alone. Both sham- and glycanase-treated cells
were loaded with the Ca21 indicator Fluo-3, and Ca21 mo-
bilization was measured in response to RANTES as de-
scribed previously (34, 35). As a specificity control for the
effect of glycanase treatment on the response elicited by
RANTES, both sham- and glycanase-treated cells were
stimulated with anti-CD3.
As shown in Fig. 9 a, sham-treated cells responded with
a rise in intracellular Ca21 when stimulated with 3 nM
RANTES. By contrast, no increase in intracellular Ca21
was observed in glycanase-treated cells in response to 3 nM
RANTES. This effect was not due to a generalized de-
crease in cellular response in the glycanase-treated cells be-
cause essentially identical Ca21 signals were observed when
both sham- and glycanase-treated cells were stimulated
with an anti-CD3 mAb (clone UCHT-1, 66 nM; Fig. 9 b).
Thus, cell surface GAGs are required for Ca21 signaling in-
duced by RANTES in primary peripheral blood T cells.
We have made similar observations for a wide array of both
CC and CXC chemokines in PBMCs (Burns, J., R.C.
Gallo, G.K. Lewis, and A.L. DeVico, manuscript in prepa-
ration), suggesting that cell surface GAGs play a key role
the Ca21 responses elicited by these agonists as well.
Discussion
In this report, we have shown that mAb 4A12 blocks
two of the biological responses elicited by RANTES, the
antiviral effect against HIV-1 and intracellular Ca21 signal-
ing, implying that the epitope recognized by this mAb
overlaps a structure that plays a role in these responses.
Epitope mapping studies suggest the GAG-binding domain
of RANTES as this structure. This suggestion was con-
firmed by studies in which heparin was used to elute
RANTES from mAb 4A12 bound to a solid surface and by
the ability of mAb 4A12 to block the binding of RANTES
to cell surface GAGs. Taken together, our studies lend fur-
ther support to the emerging importance of GAG-binding
by RANTES in its biological activities (27, 28).
The first indication of a role for GAG-binding in the bi-
ological activity of RANTES came from studies in which
removal of cell surface proteoglycans from PM1 cells re-
versed the antiviral effect of RANTES (27). Those studies
also suggested that the relative resistance of macrophages to
the antiviral activity of b-chemokines is due to the absence
of an appropriate cell surface proteoglycan. Most recently,
it was shown that the b-chemokines, RANTES, MIP-1a,
and MIP-1b, are secreted as proteoglycan complexes from
activated CD81 CTLs (28). Those studies also showed that
the ability of RANTES to inhibit HIV-1 infection of pri-
mary monocytes is dependent on interactions with GAGs.
These studies suggest a model for the biological activity of
RANTES in which cell surface proteoglycans play a key
role. Therefore, it is surprising that this domain has not
been mapped for RANTES. Our epitope mapping studies
with mAb 4A12 add new information in this regard by im-
plicating residues 55–66 in the a-helical region of RANTES
as a component of the GAG-binding domain of RANTES.
The first identification of GAG-binding domains of
chemokines came from studies of the a-chemokines PF4
(37) and IL-8 (38). It is known that the interaction be-
tween proteins and GAGs is primarily electrostatic in na-
ture (for review see reference 45), and so cationic patches
on the surfaces of chemokines are likely regions for GAG-
binding. Alignment of a-chemokine sequences reveals a
conserved cluster of basic amino acids in the COOH-ter-
minal a-helices of these molecules (for an example see ref-
erence 39). Mutagenesis of the four lysines at positions 61,
62, 65, and 66 in PF4 showed that positive charges in this
region are critical for heparin binding (37). Similarly, suc-
cessive deletion of the COOH-terminal a-helical residues
of IL-8 abrogated its ability to bind heparin (38). There is
evidence that positively charged residues interspersed among
the basic residues of the a-helix may affect the fine speci-
ficity of these chemokines for GAGs (39). Although these
studies strongly suggest that the conserved COOH-termi-
nal a-helix of a-chemokines comprises the GAG-binding
domain, the picture is more complex for b-chemokines.
Alignment of the a-helical region of RANTES, MIP-
1a, and MIP-1b shows that only RANTES has a patch of
basic residues at positions 55, 58, and 60 in its COOH ter-
minus (Fig. 10). MIP-1a has a single lysine at position 61
and MIP-1b lacks any basic residues in this region alto-
gether. Thus, other residues must contribute to GAG-binding
in these molecules. Recent mutagenesis of MIP-1a has
shown that changing the lysine at position 61 to an alanine
has no apparent effect on heparin binding (40). By contrast,
changing the arginines to alanines at positions 18, 46, and
48, one at a time, abrogated heparin binding while chang-
ing the lysine at position 46 to an alanine altered the affin-
ity of MIP-1a for heparin (42). This region is denoted as
Figure 9. Cell surface GAGs
are required for RANTES to elicit
intracellular Ca21 signals. Primary
human lymphocytes activated
with PHA for 3 d followed by
expansion in IL-2 for 9 d were
either treated with a mixture of
glycanases consisting of 1 U/ml
each of heparinase II, heparinase
III, and chondroitinase ABC (thin
lines) or medium alone (thick lines),
as described in Materials and
Methods. The cells were loaded
with the Ca21 indicator dye
Fluo-3, and intracellular Ca21
responses were elicited by either
3 nM RANTES (A) or 66 nM
anti-CD3 (clone UCHT-1; B)
and recorded by flow cytometry
as previously described (34, 35).1924 mAb against the Glycosaminoglycan Binding Domain of RANTES
cationic site 1 in Fig. 10 as the cationic character of this site is
highly conserved among RANTES, MIP-1a, and MIP-1b.
The conservation of this site among these chemokines con-
trasts sharply with the cationic site 2 shown in Fig. 10 that
exists only in RANTES in this comparison. Cationic site 2
is located in the a-helical region of RANTES and this site
is located at z458 to the highly conserved cationic site 1 in
the structure shown in Fig. 4. Our studies are most consis-
tent with mAb 4A12 recognizing an epitope that overlaps
cationic site 2, implicating this site in the recognition of
GAGs by RANTES. Three observations support this con-
clusion.
First, removal of residues 55–66 abrogates reactivity with
mAb 4A12. Analysis of Peak 4 in Fig. 3 showed that the
epitope recognized by mAb 4A12 is independent of resi-
dues 67 and 68. Furthermore, the molecule found in Peak
3 (Fig. 3) was unreactive with mAb 4A12 and this was
comprised of disulfide bonded fragments of RANTES cor-
responding to residues 1–54 with a cleavage at the glutamic
acid located at position 26. Thus, it is possible that removal
of residues 55–68, cleavage at glutamic acid 26, or both,
abrogates the binding of mAb 4A12. Our data are most
consistent with the involvement of residues 55–66 in the
epitope recognized by mAb 4A12. Glutamic acid 26 is
conserved between human and murine RANTES and
studies have shown that mAb 4A12 does not recognize the
latter (data not shown). Therefore, it is unlikely that the
epitope recognized by mAb 4A12 includes this residue.
Furthermore, glutamic acid 26 is located on the back sur-
face of RANTES in Fig. 4 and is away from the a-helix or
cationic site 1, making it unlikely that cleavage of this resi-
due would contribute significantly to the loss of reactivity
for this epitope. By contrast, residues 55–66 overlap cat-
ionic site 2 and harbor amino acids that are not conserved
between human and murine RANTES or among human
RANTES and MIP-1a or MIP-1b.
Second, as mentioned above, studies have shown that
mAb 4A12 does not recognize murine RANTES. Except
for a conserved lysine to arginine substitution at position
45, cationic site 1 is completely conserved between these
two species of RANTES. By contrast, there is an arginine
to glutamine change at position 59 in cationic site 2 and a
nonconservative serine to tyrosine change at position 64
that is located on the same face of the a-helix as cationic
site 2 when comparing human and murine RANTES.
Thus, our data are most consistent with mAb 4A12 recog-
nizing a discontinuous epitope that overlaps the a-helix of
RANTES, which harbors cationic site 2. This epitope
would be critically dependent on the residue at position 64.
Third, preliminary studies showed that mAb 4A12 does
not recognize either MIP-1a or MIP-1b. These b-chemo-
kines also have nonconservative amino acid changes at po-
sition 64. Both MIP-1a and MIP-1b have an aspartic acid
at position 64 compared with the serine at this position in
RANTES, consistent with the loss of reactivity of mAb
4A12 with murine RANTES that has a tyrosine at this po-
sition. Taken together, our data strongly suggests that mAb
4A12 recognizes an epitope that overlaps the a-helix of
RANTES. Furthermore, these data suggest that this region
contributes to the GAG-binding domain of this chemokine.
In the discussion above, it should be noted that the resi-
dues implicated in the binding of mAb 4A12 and GAGs do
not overlap those reported previously to affect the binding
of RANTES to CCR1, CCR3, and CCR5 or to affect the
ability of RANTES to signal via these receptors (46). In
those studies, residues 1–4, 6, 7, 12, 14, 15, and 17 contrib-
uted to the interaction between RANTES and CCR1,
CCR3, or CCR5. The precise roles of these residues var-
ied with the assay (binding or signaling) and with the re-
ceptor (CCR1, CCR3, or CCR5), but the results clearly
implicate the first 17 amino acids in the interaction of
RANTES with its canonical 7-transmembrane domain G
protein–coupled receptors. Although it can not completely
be ruled out that the epitope recognized by mAb 4A12
could overlap these residues instead of residues 55–66, we
consider this unlikely for the following reasons. Our data
shows that mAb 4A12 recognizes an epitope overlapping
the GAG-binding domain. This is shown by the ability of
mAb 4A12 to block the binding of RANTES to cell sur-
face GAGs and by the ability of heparin to elute RANTES
from immobilized mAb 4A12. The data reported in refer-
ence 48 are not consistent with first 17 residues of RANTES
affecting GAG-binding. Some of the mutations described
in reference 48 differentially affected the binding of RANTES
to 3T3 cells transfected with either CCR3 or CCR5. Since
3T3 cells were used as the parent in both transfections, the
observed differences are due to the 7-transmembrane re-
ceptor and not to GAG-binding. Thus, the residues of
RANTES involved in receptor binding versus GAG-bind-
ing must lie in different regions of the molecule.
Our data and the reports cited above strongly suggest
that the GAG-binding domain and the 7-transmembrane
binding domain of RANTES are not congruent; however,
as pointed out above, they could overlap with one another
and with the epitope recognized by mAb 4A12. In this re-
Figure 10. Multiple alignment of b-chemokine sequences. Multiple
alignment of RANTES, MIP-1a, and MIP-1b was carried out using the
default settings for the ClustalW subroutine of MacVector (version 6.01;
Oxford Molecular, Inc., Oxford, England, UK). The following sequences
were obtained from the specified databases via NCBI Entrez and used for
the alignments: Swiss-Prot accession number P13501, human RANTES;
Swiss-Prot accession number P30882, murine RANTES; Genbank acces-
sion number L10918, human MIP-1a; and Swiss-Prot accession number
P13236, human MIP-1b.1925 Burns et al.
gard, it should be noted that a mutant MIP-1a that lacks
the ability to bind heparin also failed to bind to CCR1
(47). Although our results clearly show that the ability to
bind GAGs is necessary for the antiviral effect against HIV-1
and the ability of RANTES to elicit intracellular Ca21 sig-
naling, they do not speak directly to the potential overlap
between the functional domains of RANTES. This possi-
bility must be kept in mind in any analysis of the mecha-
nisms by which b-chemokines bind to cell surfaces to elicit
specific biological responses. At the minimum, our data ar-
gue strongly that 7-transmembrane receptors alone are not
sufficient for the two responses evaluated in this report, the
antiviral effect and Ca21 signaling.
Although our data show that the epitope recognized by
mAb 4A12 overlaps the GAG-binding domain of RANTES,
the paradoxical pattern of binding determined by the order
of reagent addition requires additional comment. This
binding pattern is most consistent with the ability of cell
surface GAGs to induce the oligomerization of RANTES
(41). In our studies, preincubation of RANTES with mAb
4A12 blocked the binding of RANTES to cell surfaces as
judged by flow cytometry. It is likely that preincubation of
the reagents works this way because mAb 4A12 blocks the
initial “seeding” of the cell surface GAGs with RANTES,
thereby preventing oligomerization. On the other hand,
preincubation of the cells with RANTES followed by de-
tection with mAb 4A12 allows the concentration-depen-
dent oligomerization of RANTES by cell surface GAGs.
This would allow some GAG-binding sites on the ends of
the oligomers to remain free and detectable by mAb 4A12.
Consistent with this observation, the epitope recognized by
mAb 4A12 is exposed on the free ends of oligomeric
RANTES as judged by molecular modeling. Our studies
showing that removal of GAGs by glycanase treatment re-
duces the signal in assays where RANTES is preincubated
with cells before detection by mAb 4A12 are consistent
with this interpretation. This conclusion is also supported
by our flow cytometry studies in which we were unable to
obtain saturable binding by RANTES detected by mAb
4A12. Thus, most of the binding seen by flow cytometry
when cells are preincubated with RANTES is dependent
upon GAG binding and not binding to a 7-transmembrane
receptor. In our hands, it requires .30 nM RANTES to
begin to detect a signal by flow cytometry, which is 30–
100-fold above the dissociation constant reported for the
binding of RANTES to the 7-transmembrane receptors
CCR1, CCR3, and CCR5 (46). Subsequent studies in our
group using 125I-RANTES allows detection of binding in
the range of 0.1–1.5 nM, but even at these concentrations
.50% of the binding is sensitive to removal of GAGs (our
manuscript in preparation). Thus, any binding experiment
done using RANTES must take into account the interac-
tion between the chemokine and GAGs in addition to the
binding due to the interaction of this chemokine with the
7-transmembrane receptors.
The recognition of the GAG-binding domain by mAb
4A12 raises the question of how this mAb blocks the anti-
viral effect of RANTES. The best model based on current
information would be that only GAG–RANTES com-
plexes interact with the 7-transmembrane receptor in a way
that prevents the ability of HIV-1 to use it as a coreceptor.
In this case, mAb 4A12 would block the antiviral effect by
simply blocking the formation of these complexes. This
model is consistent with the studies showing that cell sur-
face GAGs enhance the anti-viral effect (27) of RANTES
in lymphoid cells and that soluble GAG-RANTES com-
plexes are strongly anti-viral for peripheral blood macrophages
(28). Although this model is currently under evaluation in
our group, the data presented above show that mAb 4A12
blocks the intracellular Ca21 response elicited by RANTES
in addition to blocking the antiviral effect. This suggests
that GAGs play a role in the ability of RANTES to signal
cells as well. This has been confirmed by experiments in
which removal of cell surface GAGs abrogates the intracel-
lular Ca21 response elicited by RANTES, arguing that
GAGs play a much broader role than previously suspected
in the biological responses to this chemokine. In summary,
the data presented above strongly support a role for GAGs
in the biological activities of RANTES and suggest that
GAGs must be considered along with the canonical 7-trans-
membrane domain receptors in studies attempting to under-
stand the biology of this chemokine.
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